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Phytosterols (PS) have long been recognized for 
their cholesterol-lowering action, however, recent 
work has highlighted triglyceride (TG)-lowering 
responses to PS that may have been overlooked 
in previous human interventions and mechanistic 
animal model studies. This review assesses the 
current state of knowledge regarding the effect 
of dietary PS supplementation on blood TG 
concentrations by examining the average therapeutic 
response, potential mechanisms, and metabolic 
and genetic factors that may contribute to inter-
individual variability. Data from human intervention 
trials demonstrates that, compared to baseline 
concentrations, PS supplementation results in 
a variable TG-lowering response ranging from 
0.8 to 28%. It is evident that hypertriglyceridemic 
individuals (>1.7 mmol/L) have a greater TG-lowering 
response to PS (11–28%) than subjects with normal 
plasma TG concentrations (0.8–7%). Although a 
genetic basis for the variable TG-lowering effects of 
PS is probable, there are only limited studies to draw 
on. The available data suggest that polymorphisms 
in the apolipoprotein E (apoE) gene may affect 
responsiveness, with PS-induced reductions in TG 
more readily evident in apoE2 than apoE3 or E4 
subjects. Although only a minimal number of animal 
model studies have been conducted to specifically 
examine the mechanisms whereby PS may reduce 
blood TG concentrations, it appears that there 
may be multiple mechanisms involved including 
interruption of intestinal fatty acid absorption and 
modulation of hepatic lipogenesis and very low 
density lipoprotein packaging and secretion. In 
summary, the available data suggest that PS may be 
an effective therapy to lower blood TG, particularly 
in hypertriglyceridemic individuals. However, before 
PS can be widely recommended as a TG-lowering 
therapy, studies that are specifically powered and 
designed to fully access therapeutic responses and 
the mechanisms involved are required. 
Since discovery of the association between elevated blood cholesterol and increased cardiovascular disease (CVD) risk, early animal (1) and epidemiological investigations (2), 
diet-based and pharmacological cholesterol-lowering therapies 
have become integral components of primary and secondary 
CVD prevention programs. Although these therapies have largely 
reduced the prevalence of high low-density lipoprotein cholesterol 
(LDL-C) among Americans, close to 33% of U.S. adults still have 
elevated LDL-C, and there is concern that high-risk individuals 
often fail to meet their LDL-C target goals. 
Phytosterols (PS), plant-based sterols that structurally 
resemble cholesterol, are arguably the best-defined nutraceutical 
approach to reduce blood cholesterol concentrations by 
interfering with intestinal cholesterol absorption. PS have a 
proven track record as ‘natural’ cholesterol-lowering agents 
with consistent LDL-C reductions in the range of 8–16% 
in numerous well-controlled clinical interventions (3) and 
preclinical studies that have defined the molecular mechanisms 
involved (4–6). Although PS are highly regarded as effective 
for reducing circulating total cholesterol and LDL-C, they were 
traditionally believed to have no effect on triglyceride (TG) 
concentrations, an important independent CVD risk factor. 
However, recent animal and human studies have highlighted 
a potential role for PS in regulating blood TG concentrations 
[Table 1 (7–19) and Table 2 (20–40)]. That the TG-lowering 
properties of PS are just now surfacing may seem unexpected 
given that their health benefits have been actively researched 
in controlled human studies since the 1950s. However, a 
close assessment of previous clinical PS interventions reveals 
TG-lowering responses that may have been overlooked for 
a variety of reasons. First, the lipid hypothesis placed such a 
major emphasis on cholesterol as the major CVD risk factor 
that PS interventions were specifically designed and statistically 
powered to detect movement in the primary endpoint of LDL-C, 
not other lipid risk factors. Furthermore, recent work suggests 
that the TG lowering responses of PS are most clearly observed 
in hypertriglyceridemic individuals; however, the vast majority 
of PS interventions were designed with hypercholesterolemia 
as the main study inclusion criteria. Finally, the TG-lowering 
action of PS may have been difficult to discern as metabolic and 
genetic factors may contribute to a relatively variable response 
compared with the more consistent reductions observed in 
circulating cholesterol levels. 
This review will provide a thorough assessment of the effects 
of PS on TG metabolism with discussion of the TG-lowering 
effects reported in previous clinical interventions and what is 
known regarding the potential molecular mechanisms that may 
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Table 2. Selected preclinical studies reporting plasma and/or tissue triglyceride responses following phytosterol/
phytostanol supplementation
Author Model Diet and Design Result Notes
Hamster model
Rideout et al. (20) Male Syrian golden Semisynthetic ‘Western’ diet 
2% PS supplementation  
(Reducol) 
 
6 weeks feeding
↓ blood TG (49%) 
 
Shift in hepatic FA (↑ 16:0; ↓16:1 
and 18:1 
 
↓ de novo lipogenesis (44%) 
 
↓ intestinal SREBP1c, hepatic 
PPARα, and FAS mRNAb
Comparable TG reductions to  
ezetimibe supplementation 
 
Reductions in blood and hepatic 
cholesterol levels also observed
Ntanios et al. (21) Male and female  
Syrian golden
Semisynthetic diet  
supplemented with PS (0.5 or 
1%) from tall oil or soybean oil 
 
Approximately 13 weeks feeding
↓ blood TG in males fed 1% soybean 
oil-PS (no % given)
No effect in female hamsters
Ntanios et al. (22) Male F1B Syrian golden Semisynthetic diet enriched  
with graded doses of  
phytosterol ester (0.24–2.84%).
↓ blood TG in animals fed >0.96% 
phytosterol ester (0.96, 1.92, 2.84%)
Vanstone et al. (23) Male Syrian golden Semisynthetic diet; tall oil or 
soybean oil derived PS  
supplemented in diet or  
subcutaneously injected 
(matched to 5 mg/kg BW/day) 
 
Approximately 9 weeks feeding
↓ blood TG (-42%) in animals in-
jected with soybean oil derived PS 
Jain et al. (24) Male Syrian golden Semisynthetic, cholesterol- 
enriched diet with sitostanol 
(0.5%)
↓ blood TG (–22%) in sitostanol 
group compared with control
Liang et al. (25) Male Syrian golden Semisynthetic, cholesterol-
enriched diet supplemented  
with sitosterol or stigmasterol 
(0.1%)
↓ blood TG (–28%) in both groups ↓ in intestinal mRNA expression 
of microsomal triglyceride transfer 
protein in both groups
Ebine et al. (26) Male Syrian golden Semisynthetic, cholesterol-
enriched diet supplemented  
with 0.7 and 1.4% disodium 
ascorbyl phytostanyl phosphatea
↓ blood TG (–45%) in 1.4% supple-
mented group
Mouse model
Rideout et al. (27) Male C57BL/6J Semisynthetic ‘Western’ diet 
2% PS supplementation  
(Reducol) 
 
6 weeks feeding
↓ blood TG (–28%) 
 
↓ hepatic TG (30%) 
 
↑ fecal 16:0 and 18:0 excretion 
 
↑ hepatic SREBP1c and FAS mRNA; 
↓ intestinal PPARα mRNA 
 
↑ de novo lipogenesis (23%)
Blood total cholesterol not altered 
 
No change in a host of intestinal FA 
absorption and metabolism gene 
expression
Volger et al. (28) Female apolipoprotein 
E*3-Leiden transgenic
Semisynthetic containing 0.25% 
cholesterol and 0.0, 0.25, 0.5, 
0.75, or 1.0% plant stanols 
8 weeks feeding
↓ hepatic TG (–38%) in the 1% 
dietary stanol group 
No effect on serum TG 
 
No effect on hepatic VLDL-TG 
secretion
Plosch et al. (29) Male C57BL/6J Semisynthetic cholesterol 
supplemented diet with 0.5% 
plant sterols or stanols 
 
4 weeks feeding
↓ hepatic TG in both sterol and stanol 
groups
No change in plasma TG  
concentrations
Brufau et al. (30) Male C57BL/6J Semisynthetic cholesterol 
supplemented diet with 1, 2, 4,  
or 8% plant sterols 
 
2 weeks feeding 
↓ blood TG (–26%) in 4% supple-
mented group 
 
↑ hepatic TG (59%) in the 2% 
supplemented group
Looije et al. (31) Male C57BL/6J Low fat semisynthetic diet 
supplemented with 2% FM-VP4a
↓ blood TG (% reduction not speci-
fied)
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Table 2. (continued)
Author Model Diet and Design Result Notes
Lukic et al. (32) Male apoE knockout Cholesterol-supplemented  
chow diet with 0.1, 0.5, 1.0, and 
2.0% FM-VP4a  
 
12 weeks feeding
↓ blood TG in 2% supplemented 
group at 4 and 8 weeks
Schonewille et al. 
(33)
Male C57BL/6J Semisynthetic high fat/ 
cholesterol diet supplemented 
with 3.1% plant sterols or  
stanol esters
↓ blood TG 
 
No effect on hepatic TG levels
Down regulation of LXR target 
genes in liver including ATP binding 
cassette A1, G5, and G8, and sterol 
regulatory element binding protein 
1c c
Rat model
Matasuoka et al. 
(34) 
Male Sprague-Dawley 
rats
Semisynthetic diet  
supplemented with 0.5% free 
PS (FPS) or free PS egg yolk 
lipoprotein complex (PSY) 
 
3 weeks feeding
↓ hepatic TG in both groups (FPS, 
–33%; PSY, –22%)
No change in serum TG  
concentrations
Awaisheh et al. (35) Male Sprague-Dawley 
rats
Semipurified high fat/cholesterol 
chow; daily gavage with  
nonfermented milk with and 
without PS (5 mg/mL) 
 
8 weeks feeding
↓ blood TG (–16%) 
 
↓ hepatic TG (–92%)
Ikeda et al. (36) Male Sprague-Dawley 
rats
Semisynthetic diet  
supplemented with  
campestenone (0.5%)
↓ blood TG (–76%) 
 
↓ hepatic TG (–69%) 
 
↑ expression of β-oxidation genes 
 
↓ hepatic SREBP1c expression
Tomoyori et al. (37) Male Sprague-Dawley 
rats
Semisynthetic supplemented 
with 0.25% PS
↓ lymphatic transport of TG
Pig model
Brufau et al. (38) Female Dunkin Hartley 
guinea pigs
Cholesterol enriched (0.33%), 
isocaloric diets, chow versus 
semisynthetic not specified;  
Supplemented with three doses 
of PS (0, 1.27, and 2.45%); 
 
Diets with combination pectin 
and PS were also examined 
4 weeks feeding
↑ apparent absorption of saturated 
FA in PS-supplemented animals 
including lauric (12:0) and myristic 
(14:0) acids 
 
↑ hepatic incorporation of lauric 
(12:0) and myristic (14:0) acids in 
PS-supplemented animals versus 
animals fed saturated fat diet
Brufau et al. (39) Female Dunkin Hartley 
guinea pigs
↓fecal excretion of lauric (12:0) and 
myristic (14:0) acids compared with 
high saturated fat diet 
 
↑ fecal excretion of arachidic (20:0) 
and behenic (22:0) acids compared 
with high saturated fat diet
Brufau et al. (40) 
 
Female Dunkin Hartley 
guinea pigs  
No change in plasma TG 
 
a  A semisynthetic esterified phytostanols-ascorbic acid derivative.
b  SREBP1c = Sterol regulatory element binding protein 1c, PPARα = peroxisome proliferator receptor alpha, and FAS = fatty acid synthase. 
c  LXR = Liver x receptor and ATP = adenosine triphosphate.
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underlie these responses. We review the extent of our knowledge 
regarding the metabolic and genetic factors that are thought to 
influence these responses and discuss future research priorities 
that must be addressed to more fully evaluate PS as a potential 
TG-lowering therapy.
Clinical Assessment of TG Lowering in Response to PS
A review of the clinical trial database demonstrates a 
TG-lowering effect of PS ranging from 0.8 to 28% compared to 
baseline values (7–19). The TG-lowering responses of selected 
studies are presented in Table 1.
A purview of this data demonstrates that, for the 
most part, the TG-lowering efficacy of PS increases as 
baseline TG levels become more prominent. For example, 
in studies where subjects were hypertriglyceridemic 
(>1.7 mmol/L), 1.6–4 g/day PS lowered circulating TG levels 
11–28% (8, 10–14, 18). Conversely, in studies where baseline 
TG levels were <1.7 mmol/L, 1.6–4.1 g/day PS lowered TG 
levels by 0.8–7% (7, 11, 12, 15, 16, 19). Pooled analysis of 
five clinical studies showed that subjects with baseline TG 
concentrations of 1.0 mmol/L experienced a 1.0, 3.8, and 4.7% 
reduction in circulating TG levels with 2.0, 3.0. or 4.0 g/day plant 
stanols, respectively (40). However, across the same dosages 
of PS, when baseline TG values were 2.0 and 3.0 mmol/L, TG 
levels were decreased by approximately 1.5 and 2.0%, 5.8 and 
7.8%, and 7.0 and 9.7%, respectively (41). Using data from 
12 clinical trials, Demonty et al. (42) showed PS facilitated a 
mild decrease in circulating TG of 6.0%. However, with the 
exception of two subjects with mildly elevated baseline TG 
levels (1.73 and 1.93 mmol/L), baseline TGs were relatively 
normal. Therefore, the 6.0% reduction in circulating TG aligns 
with data demonstrated in Table 1. In the same study, when 
the data were stratified by baseline TG levels, PS lowered TG 
concentrations by 0.18 mmol/L in subjects with TG levels 
within the 75th percentile (1.9 mmol/L; 42). This reduction 
is substantially greater than the 0.0006 and 0.08 mmol/L 
decrease in circulating TG concentrations among subjects with 
baseline TGs within the 25th (0.99 mmol/L) and 50th percentile 
(1.36 mmol/L), respectively (42). To date, only one clinical 
trial, by Theuwissen et al. (10), has sought to delineate PS 
TG-lowering efficacy. Using subjects with baseline TG levels 
of at least 1.73 mmol/L, PS had no effect on circulating TG 
concentrations. However, among subjects with moderate-to-
high baseline TG levels (>2.3 mmol/L), 2.5 g/day PS lowered 
TG concentrations by 11% compared with baseline. It is noted 
that among normotriglyceridemic subjects (1.2 mmol/L), 
Davidson et al. (17) observed a 13.3% decrease in TG levels 
with 3.0 g/day. However, no effect was demonstrated with 
6.0 and 9.0 g/day PS (17). While the TG-lowering results 
outlined in Table 1 are promising, a more focused approach for 
delineating PS effects on circulating TG is required. Overall, 
data suggest that 2.0–4.0 g/PS/day facilitates significant 
reductions in circulating TG levels in humans. However, the 
degree of PS-induced TG lowering could be dependent on the 
presence and magnitude of hypertriglyceridemia.
In addition to applying hypertriglyceridemia as inclusion 
criteria in future clinical trials, future studies should also consider 
the consistency as to how the TG-lowering response is reported. 
Table 1 shows that the TG-lowering efficacy of PS is reported 
as comparisons to baseline, the control group, or both. This is 
problematic when comparing the effects PS on circulating TG 
levels between studies. For example, Jones et al. (18) reported 
that, compared to baseline, hypertriglyceridemic subjects 
receiving 1.84 g/day PS decreased circulating TG by 18.9 and 
17.4%, respectively. However, compared to the control group, 
TG levels were modestly decreased by 1.0% (18). Shaghaghi 
et al. (19) demonstrated the opposite effect, where 2.0 g/day 
PS decreased TG relative to baseline and the control group 
by 0.8 and 13.9%, respectively. Large disparities in relative 
reductions in TG between baseline and controls values could 
suggest that baseline TG levels, background diets, or other 
lifestyle factors are imposing a substantial effect on the TG 
response. Perhaps consistent reporting of absolute TG reductions 
would address the abovementioned discrepancies in data that 
support the effects of PS on elevated TG concentrations. 
Preclinical Assessment of TG-Lowering in Response 
to PS
Several animal species, namely, hamsters, mouse, and 
rat models, demonstrate fairly consistent reductions in both 
blood and hepatic TG concentrations following dietary PS 
incorporation (Table 2). It is of interest to note that these TG 
reductions are evident despite drastic differences in study design, 
including diverse animal models with distinct lipid metabolism 
and different background diets (chow versus semisynthetic) 
with variable types of fat and wide-ranging sources and 
supplementation levels of PS. With a few exceptions, most of 
these studies were designed to specifically examine cholesterol-
lowering responses and associated mechanisms; however, 
results of these studies do shed light on potential pathways by 
which PS may directly or indirectly modulate TG metabolism 
(Figure 1). 
There are multiple lines of evidence to suggest that at least 
part of the TG-lowering response to PS is related to alterations 
in TG and/or fatty acid (FA) metabolism within the intestine. In 
what we believe to be one of the first studies explicitly designed 
to examine the TG-lowering mechanisms of PS, we fed male 
1 
Figure 1. Potential mechanisms involved in the triglyceride-
lowering response to physterols/phytostanols.
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C57BL/6J mice a semisynthetic ‘Western’ diet supplemented 
with 2% PS (Reducol) for 6 weeks. Wild type C57BL/6J mice 
are a unique model as they exhibit reductions in blood and 
hepatic TG following PS supplementation but are considered 
nonresponders to the cholesterol-lowering action of PS due to 
their high cholesterol synthetic capacity (43). Compared with 
unsupplemented animals, PS-fed mice exhibited reductions in 
plasma (28%) and hepatic (30%) TG concentrations. At least 
part of this TG lowering response was associated with changes in 
intestinal fat metabolism including increased fecal FA excretion, 
specifically fecal palmitate and stearate. Supporting a potential 
role of PS in reducing intestinal TG absorption, Tomoyori et al. 
reported that PS reduced the postprandial lymphatic transport 
of TG (5–7 h following a meal) in thoracic duct–cannulated 
Sprague-Dawley rats (37). In our mouse study, we detected 
no difference in the expression of a host of intestinal genes 
related to FA absorption and chylomicron assembly; however, 
PPARα mRNA expression was reduced compared with control 
animals (discussed below). These results may suggest a 
physical interference of PS on intestinal FA absorption rather 
than a direct effect on the expression of genes and proteins that 
regulate FA uptake, similar to the interference of PS with the 
incorporation of cholesterol into bile salt micelles. Alternatively, 
Liang et al. reported that male Syrian golden hamsters exhibited 
a 28% reduction in blood TG that was associated with reduced 
mRNA expression of intestinal microsomal triglyceride 
transfer protein (MTP) following dietary supplementation with 
sitosterol or stigmasterol (0.1%; 25). As MTP plays a pivotal 
role in the assembly and secretion of apolipoprotein B (apoB)-
containing chylomicron particles, PS-mediated reductions 
in the expression of this gene could conceivably be linked to 
TG lowering and should be confirmed in future mechanistic 
studies. Although many studies (both animal and human) have 
directly examined intestinal cholesterol absorption in response 
to PS consumption, we are not aware of any studies that have 
employed stable-isotope methodology to directly measure FA 
absorption following PS intervention. This is a major knowledge 
gap in our understanding of the potential mechanisms involved 
in PS-mediated TG reductions and should be addressed in future 
animal and human studies. 
As mentioned above, in a previous study designed to examine 
the TG lowering responses of PS, we have observed reductions 
in intestinal peroxisome proliferator-activated receptor alpha 
(PPARα) mRNA expression (27). PPARα is a nuclear receptor 
highly expressed within intestinal enterocytes that mediates the 
effects of nutrients, specifically FA, on gene expression. PPARα 
activation has been shown to regulate a whole host of intestinal 
functions including nutrient transport, fatty acid oxidation, 
oxidative stress, and inflammation, and its expression pattern 
mimics that of other critical genes involved in FA absorption (44–
46). The broad scope of its regulation and constant exposure 
to its FA ligands makes PPARα an intriguing therapeutic target 
for obesity and dyslipidemia. At this point, it is difficult to say 
whether the observed reduction in PPARα mRNA expression is 
a direct effect of PS or an indirect consequence, possibly from 
a direct interference of PS with intestinal TG digestion and FA 
absorption. 
There is also evidence to suggest that PS directly or indirectly 
influence hepatic FA and TG metabolism. The liver is central 
to whole-body FA and TG metabolism as a primary site for 
the de novo lipogenesis of FA, the synthesis and secretion 
of nascent very low density lipoprotein (VLDL) particles, 
and the clearance of FAs from TG-rich remnant lipoprotein 
particles and high density lipoprotein (HDL) species. PS 
supplementation is regularly associated with a reduction in 
hepatic TG concentrations in hamster, mouse, and rat models 
(Table 2). In addition to tissue TG concentrations, there is also 
evidence to suggest that PS may modulate the hepatic FA profile. 
We observed a shift in hepatic fatty acid composition toward 
increased saturated 16:0 (approximately 50%) and reduced 
monounsaturated FA (16:1, approximately 40% and 18:1, 
approximately 24%) in PS-supplemented hamsters compared 
with unsupplemented animals (20). Similarly, Brufau et al. 
also observed an increase in the hepatic incorporation of lauric 
(12:0) and myristic (14:0) acids in PS-supplemented female 
Dunkin Hartley guinea pigs versus animals fed a saturated fat 
diet (38). The implications of this apparent shift in hepatic FA 
toward a more saturated profile is not yet known, although it 
may be a secondary effect due to a reduction in intestinal 
TG absorption or modulation of hepatic lipogenesis and/or 
lipoprotein synthesis. In support of a TG-lowering mechanism 
of hepatic origin, a recent study reported a reduction in hepatic 
VLDL secretion in male C57BL/6J mice fed a high fat diet 
supplemented with 3.1% PS or stanol esters for 3 weeks (33). 
Furthermore, in a human study, Plat et al. reported a reduction 
in large and medium plasma VLDL particles in dyslipidemic 
metabolic syndrome subjects consuming 2 g of PS provided in 
a yogurt drink matrix (11).
We have investigated the modulation of hepatic de novo 
lipogenesis as a potential mechanism that may underlie TG 
reductions following PS supplementation in both mouse 
and hamster models (20, 27). However, the results of these 
studies highlight differential model-specific responses that 
preclude any clear consensus regarding the impact of PS 
on hepatic lipogenesis. We observed an increase in hepatic 
de novo lipogenesis in PS-fed C57BL6 that we interpreted 
to be a compensatory response to interference with intestinal 
FA absorption as evidenced by increased fecal FA excretion. 
We have recently identified a similar response in a PS-fed 
Zucker rat model that demonstrated an increase in the ratio of 
hepatic 16:0/18:2n-6, an indirect measure of hepatic de novo 
lipogenesis (Rideout et al., unpublished). However, in a separate 
study, PS fed Syrian golden hamsters exhibited a reduction in 
de novo lipogenesis that was supported by a decrease in the 
protein abundance of FA synthase, a rate-limiting enzyme 
in the lipogenic pathway. Given the similarity in the design 
factors between the two studies, including background diet, 
PS supplementation level, and stable isotope analysis, this 
discrepancy highlights the underlying differences in lipid 
metabolism between mouse and hamster species and clearly 
demonstrates the need for estimates of de novo lipogenesis as 
part of a mechanistic human intervention. 
It is of interest to note that lipid reductions (both cholesterol 
and TGs) have been reported following intraperitoneal and 
subcutaneous PS injections in various animal models (47–49). 
Vanstone et al. (23) observed TG reductions in Syrian golden 
hamsters subcutaneously injected with PS at a dose of 
5 mg/kg/body weight. These results suggest that PS may mediate 
blood lipid concentrations independent of their direct effects 
within the intestine, possibly by modulating the expression of 
genes that regulate hepatic TG balance.
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Factors Affecting Responsiveness
Recent work has highlighted a variety of subject specific 
metabolic and genetic factors that predict the magnitude 
and direction of the cholesterol response to PS (43, 50–52). 
Although less work has been done to specifically examine the 
heterogeneity of responses in blood TG, its range has been 
estimated to be between 6–20% (3). As discussed previously, 
the TG-lowering efficacy of PS seems to depend on the presence 
and magnitude of hypertriglyceridemia. This stands to reason as 
TG reductions in response to ezetimibe, the well-characterized 
intestinal cholesterol absorptive inhibitor, have also been shown 
to be dependent on baseline TG concentrations (53). 
Although a genetic basis for the variable TG-lowering effects 
of PS is probable, we are only aware of two studies that have 
examined a potential genetic link, both with polymorphisms in 
the apolipoprotein E (apoE) gene. ApoE is an apolipoprotein 
component of lipoproteins including chlyomicrons, VLDL, 
LDL, and HDL and is, therefore, heavily involved in directing 
lipoprotein metabolism and remodeling with the plasma 
compartment. ApoE is polymorphic with three common alleles 
in the population, namely ε4, ε3, and ε2, that are thought to 
underlie the lipid-lowering responses to drug and diet-based 
therapies. Sanchez-Muniz et al. observed TG reductions 
in apoE2 but not in apoE3 or E4 subjects following PS 
intervention in hypercholesterolemic adults (8). Although 
not significant, Geelen et al. reported that E4 subjects tended 
(P = 0.13) to have a greater TG-lowering response compared 
with E3/3 subjects consuming 3.2 g of daily PS in margarine 
(difference of 0.08 mmol/L; 54). There is a need to conduct 
further studies to understand the genetic basis of responsiveness 
with a focus on genes that are known to modulate plasma TG 
concentrations and lipoprotein metabolism. Furthermore, there 
has yet to be any studies to examine more readily identifiable 
patient characteristics, such as ethnicity, age, gender, and body 
mass index that may underlie the TG-lowering response to PS. 
Summary 
Although PS are well substantiated for their LDL-C lowering 
effects in hypercholesterolemic patients, the efficacy of PS as 
a TG-lowering therapy has only recently gained momentum 
within the nutrition community through a limited number of 
animal and human studies specifically designed to examine this 
response and the potential mechanisms involved. Nonetheless, 
clinical trial data have shown that, among subjects with 
hypertriglyceridemia (TG >1.73 mmol/L), 2–4 g/PS/day can 
facilitate a decrease in TG concentrations of ≥11%. Results 
from a number of different animal studies suggested that the 
TG-lowering mechanisms of PS may be multifactorial, including 
interference with FA absorption within the intestinal lumen, 
modulation of hepatic de novo lipogenesis, and a reduction in 
circulating medium and large VLDL particles. The effects of PS 
on the expression of a variety of gene and protein targets, both 
in the intestine and liver, suggest that there may be a molecular 
component to the TG-lowering response. However, to fully 
substantiate the utility of PS as a TG-lowering therapy, human 
clinical trials that are specifically powered to detect an effect of 
PS on TG concentrations in hypertriglyceridemic subjects are 
required. Furthermore, human interventions should explore a 
mechanistic basis for the TG-lowering response with a direct 
examination of FA absorption and whole-body lipogenesis in 
response to PS supplementation. Finally, responsiveness studies 
that identify both metabolic and genetic factors that determine 
the magnitude of PS-induced TG reductions will be critical in 
defining the clinical utility of PS as a TG-lowering therapy. 
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